453P - Development of skin rash within the first week is a potential surrogate marker of effect in afatinib for EGFR mutant NSCLC: Okayama Lung Cancer Stu...

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Anti-Cancer Agents & Biologic Therapy
Complications of Treatment
Lung and other Thoracic Tumours
Personalised Medicine
Presenter Akihiro Bessho
Citation Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532
Authors A. Bessho1, S. Hosokawa2, K. Hotta3, K. Kudo3, N. Nogami4, S. Kuyama5, K. Gemba6, K. Inoue7, T. Okada8, N. Takigawa9, M. Tanimoto10, K. Kiura3
  • 1Respiratory Medicine, Japanese Red Cross Okayama Hospital, 700-8607 - Okayama/JP
  • 2Respiratory Medicine, Japanese Red Cross Okayama Hospital, 700-8607 - okayama/JP
  • 3Respiratory Medicine, Okayama University Hospital, Okayama/JP
  • 4Thoracic Oncology And Medicine, Shikoku Cancer Center, Matsuyama/JP
  • 5Respiratory Medicine, Iwakuni Clinical Center, Iwakuni/JP
  • 6Respiratory Medicine, Chugoku Central Hospital, Fukuyama/JP
  • 7Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama/JP
  • 8Respiratory Medicine, Fukuyama Medical Center, Fukuyama/JP
  • 9Department Of General Internal Medicine 4, Kawasaki Medical School,Kawasaki Hospital, Okayama/JP
  • 10Hematology And Oncology, Okayama University Hospital, Okayama/JP

Abstract

Aim/Background

Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib or erlotinib, is a key drug in patiens with EGFR-mt NSCLC. Its efficacy would be predicted by development of skin rash. However, although afatinib, 2nd generation EGFR-TKI, has proved to be effective, it has not been fully evaluated if the occurrence of any toxicity is a potential surrogate for its efficacy. Now, we investigated a potential association between development of toxicity and efficacy of afatinib.

Methods

We retrospectively studied consecutive 49 patients with EGFR-mutant NSCLC who received afatinib therapy between 2009 and 2015. Relationship with several toxicities and tumor response was examined. To avoid the potential bias of early treatment failure, we excluded pts who failed to continue afatinib for more than 1week.

Results

The Grade 2 or worse common adverse events (AEs) included skin rash in 17 patients (35%), diarrhea in 19 (39%) and mucositis in 15 (31%). Of these, number of patients who developed ≥ Grade 2 AEs within the first week was 5 (10%; skin rash), 12 (25%; diarrhea) and 4 (8%; mucositis). As for objective response, 21 (43%) of the 49 had partial response. In association with AEs and antitumor effect, those who had Grade 2 or worse skin rash within the first week tended to have better tumor response as compared with those who did not have (80% vs. 39%; p = 0.077), (Table).

Relationship with early development of adverse events and response

No. of patients Response (-) No. of patients (%) Response (+)
≥ G2 hepatitis yes no 1 27 0 (0%) 21(44%) 0.382
≥ G2 skin rash yes no 1 27 4 (80%) 17 (39%) 0.077
≥ G2 diarrhea yes no 6 22 6 (50%) 15 (41%) 0.565
≥ G2 paronychia yes no 1 27 0 (0%) 21 (44%) 0.382
≥ G2 mucositis yes no 2 26 2 (50%) 19 (42%) 0.763
≥ G2 gastritis yes no 0 28 0 (0%) 21 (43%)
≥ G2 dysgeusia yes no 0 28 0 (%) 21 (43%)
≥ G2 ILD yes no 0 28 0 (0%) 21 (43%)

Conclusions

We demonstrated that early development of skin rash would predict the response to afatinib monotherapy.

Clinical trial identification

Disclosure

K. Hotta: received honoraria from Eli Lilly Japan, Taiho Pharmaceutical, Chugai Pharmaceutical and Sanofi-Aventis. N. Nogami: received honoraria from AstraZeneca, Chugai Pharmaceutical, Taiho Pharmaceutical and Boehringer Ingelheim. N. Takigawa: received honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical and Sanofi-Aventis. M. Tanimoto: received donated funds from Nihon Kayaku. K. Kiura: received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical and Sanofi-Aventis; received research donated funds from Nihon Kayaku. All other authors have declared no conflicts of interest.